Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Hypersensitivity Pneumonitis

Pulmonary & Respiratory

Hypersensitivity Pneumonitis (HP) Clinical Trials

Also called extrinsic allergic alveolitis, HP, bird fancier's lung

Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is an immune-mediated inflammatory lung disease caused by repeated inhalation and deposition of organic or inorganic antigens in the lungs, triggering complex Type III and IV hypersensitivity reactions. Common antigens include bird proteins (avian serum antigens in bird fancier's lung), mold spores (farmer's lung, bagassosis from moldy sugarcane), metal salts (metal worker's lung, beryllium disease), thermophilic actinomycetes, and isocyanates.

In plain words, hypersensitivity pneumonitis is lung swelling caused by breathing in certain substances again and again. The immune system overreacts in the lungs, causing cough and shortness of breath, and some forms can lead to scarring.

Get an email when new Hypersensitivity Pneumonitis trials open or the FDA decides. Get alerts

Hypersensitivity Pneumonitis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 6 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Corticosteroids

Hypersensitivity Pneumonitis has 1 FDA-approved medicine, 7 open or active clinical trials (6 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Hypersensitivity Pneumonitis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Hypersensitivity Pneumonitis

Three clinical forms exist: acute (symptoms 4-6 hours after exposure with fever, chills, malaise resolving within days of avoidance), subacute (symptoms over days-weeks with continued exposure), and chronic (insidious development over months-years with progressive fibrosis). Pathophysiology involves immune complex deposition in lung tissue with lymphocytic infiltration, granuloma formation, and alveolitis.

Keep reading about Hypersensitivity Pneumonitis

Acute form presents with dyspnea, cough, fever, and malaise resolving within days of antigen avoidance. Chronic form progresses to irreversible pulmonary fibrosis. High-resolution CT shows centrilobular nodules, ground-glass opacities, and fibrotic changes. Diagnosis combines clinical history, exposure assessment, serology (precipitating antibodies), and imaging.

What are the symptoms of Hypersensitivity Pneumonitis?

These are common symptoms of Hypersensitivity Pneumonitis, and how strong they are varies from person to person.

  • Dyspnea and cough
  • Fever and chills within hours of exposure
  • Fatigue and malaise
  • Weight loss in chronic form
  • Progressive airflow obstruction
  • Hypoxemia during exertion

Who gets Hypersensitivity Pneumonitis?

Can occur at any age but particularly affects adults in their 40s-60s with occupational or environmental exposures. Variable presentation between individuals based on antigen exposure intensity, duration, and host factors. Both males and females affected equally.

Genetic predisposition factors including HLA alleles being identified. More common in bird enthusiasts, farmers, agricultural workers, and those in occupational settings with repeated antigen exposure. Higher prevalence in developed nations with identified occupational exposures.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Hypersensitivity Pneumonitis?

There is currently 1 FDA-approved medication for Hypersensitivity Pneumonitis.

Corticosteroids
prednisone, prednisolone

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How Hypersensitivity Pneumonitis is diagnosed

An immune reaction to inhaled antigens (mold, bird proteins, chemicals); diagnosis depends on exposure history, imaging, and sometimes inhalation challenge, not gene testing.

Trusted Hypersensitivity Pneumonitis resources

Reputable organizations and medical references for learning more about Hypersensitivity Pneumonitis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Hypersensitivity Pneumonitis

Use this Hypersensitivity Pneumonitis clinical trial finder to see the 6 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 3 test a treatment and 4 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

7 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialRecently updatedNCT06811389

Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis

Intervention: Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP), Staying Well

Sponsor: Weill Medical College of Cornell University

The central hypothesis is that a peer coach-delivered intervention that includes cognitive behavioral principles combined with theory-driven patient education will improve health-related quality of life (HRQOL) of patients with hypersensitivity pneumonitis (HP). The goal of this ...

Ages 18 Years to 100 Years1 location
Started May 2025Updated 1 month agoEst. Dec 2026 (~1 month)
RecruitingObservational study, no treatment givenRecently updatedNCT05988437

Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis

Sponsor: Nantes University Hospital

Hypersensitivity pneumonitis (HP) is a diffuse infiltrative pneumonitis (DIP) of immuno-allergic origin, caused by exposure to one or more antigenic substances of organic origin, in genetically predisposed individuals. It can take a fibrosing form, eventually leading to chronic r...

Ages 18 Years+
Started Nov 2023Updated 1 month agoEst. May 2027 (~5 months)
RecruitingObservational study, no treatment givenUpdated a few months agoNCT05392881

Interstitial Lung Disease Research Unit Biobank

Sponsor: University of Kansas Medical Center

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Ages 18 Years+1 location
Started Aug 2021Updated 4 months agoEst. Aug 2031 (~4y 8m)
RecruitingTreatment trialNo updates in a whileNCT03800017

Skeletal Muscle Function in Interstitial Lung Disease

Intervention: Hyperoxia

Sponsor: University of British Columbia

e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD.

Ages 40 Years to 80 Years1 location
Started Aug 2024Updated 6 months agoEst. Dec 2026 (~1 month)
RecruitingObservational study, no treatment givenNo updates in a whileNCT06644144

P4O2 ILD Extension

Intervention: No Interventions

Sponsor: Amsterdam UMC, location VUmc · AbbVie + 1 more

The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fib...

Ages 18 Years to 80 Years1 location
Started Nov 2024Updated 6 months agoEst. Oct 2028 (~1y 10m)
Find Hypersensitivity Pneumonitis trials near you, ranked by distance →
Active trial locations2 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Aug 2021 to Nov 2031
2022
2024
2026
2028
2030
now
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Hypersensitivity Pneumonitis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Hypersensitivity Pneumonitis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Hypersensitivity Pneumonitis patient communities

Facebook groups, Reddit communities and YouTube channels where Hypersensitivity Pneumonitis patients, caregivers and advocacy groups talk.

Companies developing Hypersensitivity Pneumonitis treatments

Drugmakers that list Hypersensitivity Pneumonitis in their rare disease portfolio, 1 in all.

Questions people ask about Hypersensitivity Pneumonitis